SM-ARS
AI-driven small molecule drug discovery platform for rapid candidate identification and optimization.

SyntekaBio runs AI drug-discovery platforms SM-ARS, AB-ARS, NEO-ARS, DeepMatcher and LM-VS covering small-molecule, antibody and cancer-vaccine development.
syntekabio.comCrawled Nov 20, 2026
AI-driven small molecule drug discovery platform for rapid candidate identification and optimization.
AI-based antibody drug discovery platform for candidate affinity and developability prediction.
Language model technology for predicting protein-compound interactions.
AI platform for personalized neoantigen discovery and cancer vaccine design.
Review Syntekabio drug discovery pipelines powered by proprietary AI platforms.
3bmGPT: Systematic Exploration of Small-Molecule Binding via a Large Language Model Trained on Textualized Protein–Ligand Interactions. Strategic Insights and Core Findings from the Research Published in Molecules 2025, 30, 4516.
The page lists *Scientific Reports* (2022) as a journal title.
Read Blog updates and resources from Syntekabio.
Journal Title : Tissue Engineering and Regenerative Medicine
Read Publications updates and resources from Syntekabio.
Journal Title : Journal of Computational Biology
Syntekabio expands opportunities in life sciences research and industry using AI, data, and supercomputing.
Read Press updates and resources from Syntekabio.
Explore Syntekabio culture, teams, and career opportunities.
Syntekabio is an AI company that integrates life sciences, data, and supercomputing.
Syntekabio connects global partners, research networks, and AI bio capabilities.
Explore Syntekabio milestones in AI-driven drug discovery and bio innovation.
SyntekaBio cancels two supply contracts worth **530 million won** with U.S. firm Chimera, equivalent to **433% of its 2023 consolidated revenue**. The company suspends all three new drug discovery projects under the Chimera collaboration, after failing to secure **610 million won** in milestone payments. SyntekaBio also settles **120 million won** in costs related to chemical procurement and delivery, though these are not reflected in reported revenue.
Syntekabio, an AI-driven drug discovery company, has discovered hit compounds for two previously elusive drug targets in collaboration with Memorial Sloan Kettering Cancer Center (MSK). One target had stymied MSK researchers for over a decade. The breakthrough highlights AI’s role in accelerating drug discovery by overcoming long-standing scientific hurdles.
SyntekaBio postponed its **2 billion won private placement** payment deadline from September to November while targeting a **public offering of over 3 billion won**. The company recalculated required funds due to expanded **Pre-IND (Pre-Investigational New Drug) development**, holding **7.5 billion won in cash** at mid-year. Withdrawal of the small-scale public offering could trigger disclosure sanctions.
MetaVia’s **DeepMatcher® AI platform** confirms strong engagement of inflammatory and cardiometabolic targets in its collaboration with **Syntekabio**, validating key pathways for **Vanoglipel**. The findings support ongoing development of Vanoglipel for **MASH (metabolic-associated steatohepatitis)** and potential applications in **Type 2 diabetes**. The AI-driven modeling aligns with preclinical research goals for the therapeutic candidate.
SyntekaBio is transitioning its AI asset program into an **assetization phase**, focusing on restructuring or monetizing its AI-related assets. The company signals a shift in strategy to potentially unlock value from its AI initiatives.
Syntekabio, an AI-driven drug discovery firm, sees its stock drop to a one-year low. The decline follows plans to sell rights for new shares issued through a paid-in capital increase. Investors react to the potential dilution of existing shares ahead of the offering.
SyntekaBio has licensed five AI-designed multispecific antibodies to Panolos under its AI-driven asset program. The deal marks the company’s first antibody license-out, advancing commercialization of its AI-based antibody development platform. Panolos gains access to novel antibody candidates targeting multiple disease pathways simultaneously.
Syntekabio partners with US-based Metaclip Therapeutics to develop patient-customized cancer vaccines. The collaboration focuses on immuno-oncology vaccine platforms for personalized therapeutic treatments. Both companies specialize in AI-driven drug development and cancer immunotherapy research.